Program 2021 - International Lipid Expert Panel

ILEP Recommendations 2021.
Country specific
Bulgaria - Hungary

21st of October, 7 PM CEST

Moderator:

1. Current epidemiological situation of hyperlipidaemia in Hungary.

2. The unmet need in the LLT management of the highest risk patients, especially those after ACS: ILEP Recommendations 2021

3. Case report: Lipid lowering treatment in ACS patients.

4. Case report: Beyond oral therapy: lipid lowering management in FH.

5. Case reports: Can we effectively treat high Lp(a) in high risk patient.

6. Case report: Diabetes and hyperlipidaemia: an everyday challenge.

ILEP Recommendations 2021.
Country specific
Latvia - Lithuania - Estonia

13th of October, 6 PM CEST

Moderator:

1. The current epidemiological situation in the country in the relation to drugs' availability, prescription & reimbursement.

2. The unmet need in the LLT management of the highest risk patients, especially those after ACS - from ILEP Guidelines to clinical practice.

3. The current guidelines in the real-lifie practice. How to improve it?

4. Panel Discussion and Q&A

ILEP Recommendations 2021.
Country specific
Bosnia and Herzegovina - Croatia - Slovenia

7th of October, 7 PM CEST

Moderator:

1. The epidemia of lipid disorders in Bosnia and Herzegovina and in the Region. Why? How to improve it?

2. ACS patient are the highest risk of the recurrent CVD events. Is dyslipidemia therapy, including the combination therapy, might significantly improve it - ILEP recommendations.

3. Recommendations and ever-day clinical practice. Cases show we are still far from the success...?

4. Panel Discussion and Q&A

ILEP Recommendations 2021.
Country specific
Poland - Czech Republic - Slovakia

16th of September, 5-7 PM CEST

Moderator:

1. Why cannot we treat optimally our high risk patients with lipid disorders in Slovakia? Why the guidelines are so far from the clinical practice?

2. The unmet needs in the LLT management of patients with ACS. How much ILEP recommendations might improve it?

3. The current guidelines in the real-life cases.

4. Panel Discussion and Q&A

ILEP Recommendations 2021.
Country specific – Greece!

22nd of June, 7 PM CEST

Moderators:

1. Current situation of dyslipidemic patients in Greece. How to improve it?

Assoc. Prof. E. Liberopoulos
Loannina, Greece

2. Intensive lipid lowering therapy in ACS patients. Should we move to immediate combination therapy for the highest risk patients?The Greek perspective.

C. Vlachopoulos
Athens, Greece

3. Therapy adherence & lipid lowering therapy availability in Greece. Case Reports in ACS patients - what can we really do?

N. Katsiki
Thessaloniki, Greece

ILEP Recommendations 2021.
Lipids at target! Focus on Romania

7th of June, 5 PM CEST

Moderators:

1. Practical approach of the current ESC/EAS guidelines - Romanian perspective. Can we really use them in our patients?

Prof. Dragos Vinereanu, Bucharest, Romania

2. Intensive lipid lowering therapy in ACS patients, beyond guidelines and based on ILEP Recommendations

Prof. Dan Gaita, Timisoara, Romania

3. ACS patient with LDL-C 127 mg/dl, despite optimal lipid lowering therapy with statins and ezetimibe - Was he really adherent to therapy? What can we really do?

Dr. Cristian Udroiu, Bucharest, Romania

ILEP recommendation 2021 on optimal use of lipid-lowering
therapy after acute coronary syndromes

25th May, 7 pm CEST

Moderators:

1. Should we update the definition of patients at extremely high cardiovascular risk based on ESC/EAS Guidelines 2019? ILEP Recommendations 2021. What about primary prevention

(Prof. Dariusz Dudek, Cracow, Poland)

2. Intensive lipid lowering therapy and immediate combination therapy - new paradigm in the lipid management for the highest risk patients! When, whom and why?

Prof. Maciej Banach (Lodz, Poland)

3. Therapy adherence, differences in healthcare organization and lipid lowering therapy availability in CEE and SE countries. Discharge letter and coordination care - a good solution for the therapy optimization?

(Prof. Michal Vrablik, Prague, Czechia)